

TITLE OF THE INVENTION**METHODS OF PREPARATION OF LIVE ATTENUATED BACTERIAL VACCINES BY ALTERATION OF DNA ADENINE METHYLASE (DAM) ACTIVITY IN THOSE BACTERIA**

5 This application claims priority from U.S. Provisional Application Serial No. 60/439,796, filed January 14, 2003 and U.S. Provisional Application Serial No. 60/439,790, filed January 14, 2003. The entirety of each provisional application is incorporated herein by reference.

 This invention was made with Government support under Grant No.
10 MISVO81310 awarded by the U.S. Department of Agriculture-CSREES. The Government may have certain rights in this invention.

BACKGROUND OF THE INVENTION**Field of the Invention**

 The present invention relates to methods of preparation of avirulent live
15 bacterial vaccines. Particularly, the present invention relates to attenuated live bacterial vaccines of the *Pasteurellaceae* family. More particularly, the invention is directed to methods of manufacturing live attenuated bacterial vaccines by the alteration of DNA adenine methylase (Dam) expression in the veterinary pathogens *Pasteurella multocida*, *Mannheimia haemolytica*, *Actinobacillus pleuropneumoniae*,
20 *Haemophilus somnus*, *Actinobacillus suis*, and *Haemophilus parasuis*. More particularly, the inventors have discovered methods of manufacturing live attenuated bacterial vaccines wherein the alteration of DNA adenine methylase (Dam) expression in selected pathogens can be accomplished, for example, by 1) placing the *Pasteurellaceae dam* gene on a plasmid under the control of a promoter that
25 causes increased *dam* expression in the particular bacteria species and results in live attenuated bacterial vaccines, 2) altering the chromosomal promoter for the *dam* gene so as to alter the expression of Dam in any of the above listed pathogenic bacteria, or 3) mutation of the *dam* gene so as to alter the expression of Dam in any

of the above listed pathogenic bacteria. By altering Dam expression the bacteria is attenuated and suitable for use in live attenuated bacterial vaccines.

Background of the Technology

Livestock production is a major part of the world's agriculture economy. Disease annually depletes livestock populations and increases production costs. Either by prevention or post-infection treatment, the goal of limiting the impact of disease on livestock production is of great economic importance. Prior to the introduction of antibiotics, the practice of culling diseased animals and destroying them to prevent the spread of disease was, in many cases the only option open to the livestock producer.

During the past half century, the use of antibiotics has become vital for the treatment of bacterial infections in the livestock industry. The emergence of antibiotic resistance as a serious problem in human medicine has prompted concern about the public health implications of antibiotic use in agriculture. Antibiotics have been used in farm animals for three main reasons: 1) therapy to treat an identified illness, 2) prophylaxis to prevent disease in animals, and 3) performance enhancement to increase feed conversion, animal growth rate, or yield per animal.

Prevention of disease is always preferable to treatment of disease because treatments can be ineffective, costly, and due to the possibility of antibiotic resistance potentially unhealthful for consumers. The use of antibiotics as a preventive measure can also include the undesirable overuse of antibiotics.

Immunization of livestock against the effect of infectious diseases can be more effective than attempts to protect livestock with nonspecific antibiotic treatments. Conventional methods of immunization require the preparation of a vaccine using killed or weakened infectious organisms or agents. All too frequently, immunization failures in livestock might be attributed to one or more failures in the immunization process. The chemical or physical manipulations required for production of killed bacterial vaccines may alter the effectiveness of the immune response, causing vaccine failure. The immune response is very specific and the vaccine may contain organisms of the same family as the target disease, but if they are not of the same serotype (type within the family), the results may be

disappointing. Vaccines can also lack the necessary potency or purity needed to properly stimulate an immune response in the vaccinated animal. Other problems commonly encountered in the vaccination of livestock may be outdated vaccine, improper handling or mixing of vaccines, or other delivery failures. For a variety of reasons, conventional vaccination of livestock can sometimes have disappointing results. For this reason, many livestock producers continue to rely on antibiotics as an infectious disease preventive measure.

There exists therefore a need to provide an effective method of preventing disease in livestock without the potential health hazard that can be associated with the prophylactic use of antibiotics in otherwise healthy livestock. Effective vaccines would be more economical and would avoid the potential for unnecessary antibiotic usage.

The concept of the present invention includes the preparation of attenuated live bacterial vaccines for a wide variety of pathogenic bacteria. Of particular interest to the inventors are the livestock diseases caused by veterinary pathogens *Pasteurella multocida*, *Mannheimia haemolytica*, *Actinobacillus pleuropneumoniae*, *Haemophilus somnus*, *Actinobacillus suis*, and *Haemophilus parasuis*.

The association of *Pasteurella multocida* with bovine respiratory disease (BRD) has been well known since the early 1950's¹. In most survey studies of feedlot BRD, *Mannheimia (Pasteurella) haemolytica* has been the most commonly isolated species, followed closely by *Pasteurella multocida*, with fewer cases of *Haemophilus somnus*²⁻⁴. However, in some studies, *P. multocida* is the most common isolate^{5,6}, and many BRD investigators have become convinced that *P. multocida* is an important primary pathogen in BRD^{4,7}. In young dairy calves, *P. multocida* is the most frequently isolated species from cases of pneumonia^{8,9}. *P. multocida* is a commensal occupant of the upper respiratory tract of cattle⁵; the induction of disease is often associated with stress, especially from transportation. Potential virulence factors include polysaccharide capsule¹⁰, lipopolysaccharide,^{11,12} iron-regulated outer membrane proteins^{13,14}, proteases^{15,16}, neuraminidase^{16,17}, and porins^{17,18}. Recently, signature tagged mutagenesis was employed to identify 25 genes that, when inactivated, reduce virulence in the mouse intraperitoneal

model¹⁹. The predicted gene products fell into 4 categories: regulatory, biosynthetic, known virulence factors, and unknown or novel. The whole genome sequence of an avian *P. multocida* isolate was published in 2001²⁰, which allowed identification of 104 potential virulence-related genes. However, the mechanisms that control expression of these potential virulence factors have not been determined.

DNA adenine methylase (Dam) is an important virulence gene regulator in the *Enterobacteriaceae*. In *E. coli*, Dam regulates transcription of several pili operons, including the *pap* (pyelonephritis-associated pili)^{21,22}, *sfa* (S pili), *fae* (K88 pili), and *daa* (F1845 pili) operons²³, and it regulates expression of a major outer membrane protein (Ag43)²⁴. A *Salmonella enterica* serovar Typhimurium *dam* mutant strain had altered expression of more than 20 in vivo-induced (*ivi*) genes (elevated by 2- to 18-fold in a *dam* inactivated mutant compared to a wild type *dam* positive strain)²⁵.

In bacterial species that possess a *dam* gene, alteration of *dam* expression causes substantial attenuation, as well as enhanced, protective antigenicity²⁵. A *S. enterica* serovar Typhimurium *dam* mutant had a LD₅₀ that was >10⁴ higher than wild type parent strain, and it was effective as a live attenuated vaccine after a single oral dose²⁵. An overexpressing *dam* strain was also highly attenuated in mice²⁵. In *Yersinia pseudotuberculosis* and *Vibrio cholerae*, inactivation of the *dam* gene was shown to be a lethal mutation²⁶. However, plasmid-mediated overexpression of the *dam* gene in *Y. pseudotuberculosis* resulted in a >6000-fold increase in LD₅₀ in mice compared to wild type and a 5-fold defect in colonization of *V. cholerae* in a suckling mouse model compared to wild type²⁶.

Although *dam* genes have been identified in the *Pasteurellaceae* as a result of genome sequencing projects^{20,27}, there have been no reports of functional characterization of *dam* in any of these species.

SUMMARY OF THE INVENTION

This invention involves the preparation of avirulent live bacteria vaccines. The inventors have discovered methods of manufacturing live attenuated bacterial vaccines by the alteration of DNA adenine methylase (Dam) expression in pathogenic bacteria.

Exemplary of the present invention, the inventors have discovered a method of preparation of attenuated live bacteria vaccines for the *Pasteurellaceae* family and more particularly for the veterinary pathogens *Pasteurella multocida*, *Mannheimia haemolytica*, *Actinobacillus pleuropneumoniae*, *Haemophilus somnus*, *Actinobacillus suis*, and *Haemophilus parasuis*.

One embodiment of the present invention provides a method of preparation of attenuated live bacteria vaccines that includes, for example, placing the *Pasteurellaceae dam* gene on a plasmid under the control of a promoter that causes increased *dam* expression in the particular bacteria species and results in effective live attenuated bacterial vaccines. Another embodiment of the present invention provides a method of preparation of attenuated live bacteria vaccines that includes altering the chromosomal promoter for the *dam* gene so as to alter Dam expression. Still another embodiment of the present invention for the preparation of live attenuated bacterial vaccines includes the mutation of the *dam* gene so as to alter the expression of Dam in the pathogenic bacteria.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows differential digest results of *P. multocida* and *M. haemolytica*. Lane 1 shows *M. haemolytica* digested with Mbo I. Lane 2 shows, *M. haemolytica* digested with Dpn I. Lane 3 shows *M. haemolytica* digested with Sau3A I. Lane 4 shows *P. multocida* digested with Mbo I. Lane 5 shows *P. multocida* digested with Dpn I. Lane 7 shows *P. multocida* digested with Sau3A I.

Figure 2 shows differential digests results of DG105, DG98, DG105/pCLPm2, and DG105/pCLPm3. Lane 1 shows DG105 digested with *Mbo* I. Lane 2 shows DG105 digested with *Dpn* I. Lane 3 shows DG105 digested with *Sau3A* I. Lane 4 shows DG98 digested with *Mbo* I. Lane 5 shows DG98 digested with *Dpn* I. Lane 6 shows DG98 digested with *Sau 3 A* I. Lane 7 shows DG 105/pCLPm3 digested with *Mbo* I. Lane 8 shows DG105/pCLPm3 digested with *Dpn* I. Lane 9 shows DG105/pCLPm3 digested with *Sau3A* I. Lane 10 shows DG105/pCLPm2 digested with *Mbo* I. Lane 11 shows DG105/pCLPm2 digested with *Sau3A* I. Lane 12 shows DG105/pCLPm2 digested with *Sau3A* I.

DETAILED DESCRIPTION

The specific embodiment of the present invention described herein and shown in Figures 1-2 is a non-limiting example of the inventors' discovery of novel attenuated live bacteria vaccines and methods of producing the same. The detailed description of the method of vaccine preparation provided below includes the exemplary processes employed to produce attenuated live bacteria vaccines of the *Pasteurellaceae* family. It is within the concept of the present invention to produce vaccines for a wide variety of bacterial pathogens using any of the methods disclosed herein. The invention is limited only by the claims of the present application.

The following exemplary embodiments of the present invention involve the alteration of DNA adenine methylase (Dam) expression in veterinary pathogenic bacteria. The inventors have discovered that altered Dam expression in veterinary pathogens causes them to be attenuated in their natural host(s) and to be effective as live, attenuated vaccines. Of particular interest are such vaccines developed for the *Pasteurellaceae* family; to include, *Pasteurella multocida*, *Mannheimia haemolytica*, *Actinobacillus pleuropneumoniae*, *Haemophilus somnus*, *Actinobacillus suis*, and *Haemophilus parasuis*; although it is within the concept of the present invention to apply the discovery of the present invention and the methods disclosed herein to the production of a wide variety of bacterial vaccines.

As shown in the first non-limiting example provided below, the inventors discovered that an effective live vaccine can be obtained when a copy of the *dam* gene from one of the pathogens listed above is cloned into a plasmid capable of replication in the same *Pasteurellaceae* species such that it is overexpressed from either a *lac* promoter, *tac* promoter, *araBAD* promoter, *trc* promoter, *trp* promoter, T7, SP6, or T5 bacteriophage promoters, a native promoter from that species, or other appropriate promoter. The plasmid containing the *Pasteurellaceae dam* gene is then transferred into the pathogens to cause increased expression of Dam and results in the formation of a live attenuated bacterial vaccines. To ensure plasmid stability, a mutation is created in a gene located in the chromosome of the bacteria carrying the plasmid such that said bacteria cannot survive under certain conditions, and an intact copy of this mutated gene is expressed from the same plasmid carrying the *Pasteurellaceae dam* gene. This

mutation can be made in any gene essential for survival of the bacterial under certain conditions.

EXAMPLES

5 **Bacterial strains and plasmids.** A list of the bacterial strains and plasmids employed in this example of the concept of the present invention is shown in Table 1. Sources of the bacterial strain and plasmids are as shown in Table 1, with some being provided by the inventors from the study associated with this present application. *Escherichia coli* strains were grown at 37°C on Luria-Bertani (LB) agar or broth. *Pasteurella multocida* and *Mannheimia haemolytica* strains were grown at 37°C on
10 brain heart infusion (BHI) agar or broth. For plasmid maintenance, antibiotics were added to the following final concentrations: ampicillin, 200 µg/ml; kanamycin, 50 µg/ml; and streptomycin, 80 µg/ml. Isopropyl 6-D-thiogalactopyranoside (IPTG) and 5-bromo-4-chloro-3-indolyl β-D-galactopyranoside (X-gal) were used at final
15 concentrations of 80 µM and 70 µg/ml, respectively, for blue white screening on LB agar.

Table 1. Bacterial strains and plasmids

	Bacterial strain	Description	Source
	<i>Pasteurella multocida</i> 11039	Wild type serotype A1	ATCC
5	<i>Mannheimia haemolytica</i> D153	Wild type	USDA National Animal Disease Center
	<i>E. coli</i> XL1-Blue MRF'	Cloning strain contains an F' episome with <i>lacF</i> Z ΔM15 for blue white screening	Stratagene
	<i>E. coli</i> DG98	Parent strain for DG105	ATCC
10	<i>E. coli</i> DG105 Plasmid	<i>dam</i> mutant (<i>dam</i> -13, <i>lacF</i>)	ATCC
	pT7Blue	Commercial cloning vector	Novagen
	pGEM-3Z	Commercial cloning vector	Promega
	pBluescript SK-	Commercial cloning vector	Stratagene
	pCLPm1	pGEM-3Z with 1.4 kb <i>P. multocida</i> chromosomal <i>EcoR</i> I insert containing the 3' end of <i>aroB</i> and the first 672 bp of <i>dam</i>	This study
15	pCLPm2	pT7Blue with 3.0 kb insert containing <i>P. multocida dam</i> ; oriented so that <i>dam</i> is in opposite orientation from <i>lacZ</i> promoter	This study
	pCLPm3	pBluescript with same insert as pCLPm2; <i>dam</i> gene oriented so that it is expressed from <i>lacZ</i> promoter	This study
	pLS88	<i>E. coli</i> shuttle vector that replicates in <i>Pasteurellaceae</i>	33
	pLSdam	pLS88 with pCLPm3 insert; <i>lacZ</i> promoter removed	This study
	pLSdam2	pLS88 with pCLPm3 insert; <i>lacZ</i> promoter intact	This study

20 **Detection of *dam* function in *P. multocida* and *M. haemolytica*.** To determine whether *P. multocida* and *M. haemolytica* contain functional *dam* genes, the inventors used differential digestion with restriction endonucleases *Sau3A* I, *Mbo* I, and *Dpn* I²⁸. First, genomic DNA was isolated from 100 ml cultures of *P. multocida* 11039

and *M. haemolytica* D153 by phenol/chloroform extraction followed by precipitation with isopropanol ²⁹. Genomic DNA was then digested with *Sau*3A I, *Dpn* I and *Mbo* I (New England BioLabs, Beverly, MA USA) and visualized by agarose gel electrophoresis.

5 **Cloning the *P. multocida* A1 *dam* gene.** A 459 bp fragment of the *P. multocida* A1 *dam* gene was amplified from strain 11039 chromosomal DNA using primers HAPdamP1 having nucleotide sequence GGGCGCTGGAGCAGTATT (SEQ ID NO. 1) and HAPdam M1 having nucleotide sequence TGTAGCGGAGCATAAGGT (SEQ ID NO. 2), which were designed from the
10 *Haemophilus influenzae* *dam* sequence. Cycle conditions were at 95°C for 30 seconds, 66°C for 1 min, and 72°C for 45 s for 35 cycles, with an initial denaturation step at 95°C for 2 min and a final extension step at 72°C for 10 min. The 459 bp amplicon was isolated from a 0.7% agarose gel and eluted using QIAQuick Gel Extraction Kit(Qiagen, Valencia, CA USA) and used as template for a second round of PCR using the same
15 primers and conditions.

 To clone the *P. multocida* *EcoR* I fragment containing the *dam* gene, *EcoR* I digested *P. multocida* chromosomal DNA was cloned into *EcoR* I digested pGEM-3Z. Following transformation of the ligation into XL1-Blue MRF' by electroporation, white colonies were screened by colony hybridization using the 459 bp *dam* amplicon as a
20 probe. Plasmid DNA from a positive clone was isolated and found to contain a 1.4 kb insert; this plasmid was designated pCLPm1.

 Initial sequencing of the pCLPm1 insert indicated that it did not contain the 3' end of the *dam* gene. Subsequent to this cloning step, the *P. multocida* A3 chromosomal sequence became available ²⁰; therefore, the A3 chromosomal sequence
25 flanking the *dam* gene was analyzed for PCR primer suitability using Oligo version 5.0 (Molecular Biology Insights, Cascade, CO USA). Two oligonucleotide primers, Pm1219DamM having nucleotide sequence TGAGGAAACGGTCTGGTTTCTC (SEQ ID NO. 3) and Pm1223DamP having nucleotide sequence
GCTGGAAAATTGCGTCTCGTC (SEQ ID NO. 4), were selected and synthesized by
30 Sigma Genosys (The Woodlands, TX USA). Using *P. multocida* ATCC 11039

genomic DNA as the template, a 3 kilobase amplicon containing the *P. multocida dam* gene was amplified by PCR under the following cycling conditions: 95°C for 30 seconds, 64°C for 1 min, and 72°C for 2 min for 35 cycles, with an initial denaturation step at 95°C for 2 min and a final extension step at 72°C for 10 min.

5 The 3 kb *P. multocida* PCR fragment containing the *dam* gene was ligated into pT7Blue (Novagen, Madison, WI USA) by blunt end ligation using the Perfectly Blunt Cloning Kit (Novagen), followed by transformation into NovaBlue Singles Competent Cells (Novagen). Plasmid DNA was isolated from white colonies using the QIAprep spin miniprep kit (Qiagen), and one clone with the predicted insert size was selected and
10 designated pCLPm2.

Sequence determination, assembly, and analysis. To determine the complete sequence of the *P. multocida* A1 *dam* gene, portions of the pCLPm1 and pCLPm2 inserts were sequenced on both strands using the Applied Biosystems Dye Terminator Cycle Sequencing Ready Reaction Kit protocol for sequencing double stranded plasmid
15 DNA. Primers Universal and T7 were used for the initial sequencing reactions, and subsequent reactions used custom oligonucleotide primers (Sigma Genosys). Sequencing reactions were resolved on an Applied Biosystems Prism 310 Genetic Analyzer. Sequence results were assembled using SeqMan v5.0 (DNASTar, Madison, Wi.) and compared with published *dam* gene sequences using BLAST³⁰. Percent
20 identities were determined using the CLUSTAL W method³¹ with MegAlign v5.0 (DNASTar). Prokaryotic promoters were predicted with the assistance of Neural Network Promoter Prediction³². The final sequence of the *P. multocida* A1 *dam* gene was deposited in GenBank (accession AF411317).

Expression of the *P. multocida* A1 *dam* gene from a *lacZ* promoter. To
25 orient the *P. multocida dam* gene downstream of a *lacZ* promoter, the insert from pCLPm2 was subcloned into pBluescript. Using pCLPm2 DNA as template, a 3 kilobase fragment containing the *P. multocida dam* gene was amplified by PCR using AmpliTaq DNA polymerase (Perkin Elmer, Boston, MA USA) with primers T7 and U19. Optimal PCR conditions were the same as previously described for amplification
30 of the 3 kb *P. multocida dam* fragment, except the annealing temperature was changed

to 57°C for 1 min per cycle. The 3 kb band was excised from a 0.7% agarose gel, and DNA was eluted using the Qiaquick gel extraction kit. The ends of the 3 kb fragment were digested with *Bam*H I and *Sal* I and ligated into pBluescript. One clone with the predicted insert size was selected and designated pCLPm3. One end of the insert was
5 sequenced to confirm correct orientation of the *dam* gene in relation to the *lacZ* promoter using the T3 primer.

Complementation of an *E. coli dam* mutant. Plasmids pCLPm2 and pCLPm3 were transferred into *E. coli dam* mutant strain DG105 by electroporation²⁹. To assess *dam* function in the resulting strains, genomic DNA from DG105, DG105
10 with pCLPm2, DG105 with pCLPm3, and *E. coli* parent strain DG98 was isolated, digested with *Sau*3A I, *Dpn* I and *Mbo* I, and analyzed by 0.5% agarose gel electrophoresis.

Effect of *P. multocida dam* expression on spontaneous mutation frequency in *E. coli*. Overexpression of the native *E. coli dam* gene in *E. coli* causes an increased
15 spontaneous mutation frequency. To determine whether overexpression of the *P. multocida dam* gene has the same effect in *E. coli*, the inventors compared the spontaneous mutation frequencies of *dam* mutant DG105, parent strain DG98, DG105 with pCLPM2, and DG105 with pCLPm3. The spontaneous development of resistance to rifampin was used to measure mutability of the strains. Briefly, 5 ml cultures of each
20 strain were started from single colonies, incubated for 18 h, and aliquots (0.1 ml) of the diluted suspensions were spread in triplicate on BHI plates with 100 µg/ml of rifampin. The cultures were also serially diluted in phosphate buffered saline (PBS), and viable bacterial counts were determined by spreading diluted bacterial suspensions on BHI plates without antibiotics.

25 Mutation rates for each strain were determined by dividing the number of rifampin-resistant mutants by the total viable bacterial counts. Four independent replicates of the experiment were run from separate bacterial cultures, and the average mutation rates of the strains were compared by analysis of variance (ANOVA) for a randomized complete block design with run as the blocking factor. If significant
30 differences among strains were found at the 5% level of significance, means were

separated using the least significant difference test and 95% confidence intervals were calculated to characterize the biological importance of those differences. The homogeneity of variances and normality assumptions necessary for valid application of ANOVA were examined by Levene's test and by stem-and-leaf and normal probability plots, respectively. Statistical computations were performed using the SAS System for Windows, Version 8 (SAS Institute Inc., Cary NC).

Effect of *dam* overexpression in *P. multocida*. To overexpress the *P. multocida dam* gene in strain 11039, the insert from pCLPm3 was transferred into pLS88, a shuttle vector that replicates both in *E. coli* and in the *Pasteurellaceae*³³. Two pLS88 derivatives were constructed from pCLPm3: pLSdam, which has the *P. multocida dam* gene expressed from its native promoter, and pLSdam2, which has the *P. multocida dam* gene expressed from the *lacZ* promoter.

To construct pLSdam, a 1.7 kb fragment was amplified from pCLPm3 by PCR using primers T7P1 having nucleotide sequence GGATCCTGCGTTATCCCC (SEQ ID NO. 5) and CLdamM20 having nucleotide sequence TCTAGATGTTGCCAATGC (SEQ ID NO. 6). Cycle conditions were at 95°C for 30 seconds, 67.5°C for 1 min, and 72°C for 30 s for 35 cycles, with an initial denaturation step at 95°C for 2 min and a final extension step at 72°C for 10 min. The 1.7 kb amplicon was digested with *Bam*HI and *Xba* I, which removed the *lacZ* promoter, and ligated into *Bam*HI and *Xba* –digested pLS88.

To construct pLSdam2, pCLPm3 was digested with *Afl* III and *Hin*D III, followed by treatment with the Klenow fragment of DNA polymerase I to create blunt ends. The resulting 1.6 kb fragment from pCLPm3 retained the *P. multocida dam* gene downstream of the *lacZ* promoter. The 1.6 kb fragment was excised from a 0.7% agarose gel, eluted using the Qiaquick gel extraction kit, and ligated into *Eco*R V-digested pLS88.

Both pLSdam and pLSdam2 were transferred into *P. multocida* 11039 by electroporation using described conditions³⁴ with a BioRad Gene Pulser II. Spontaneous mutation frequencies were determined for wild type strain 11039, 11039 with pLSdam, and 11039 with pLSdam2 by measuring the development of rifampin

resistance using the method described above for *E. coli* strains. Five individual replicates were run for each strain: 11039, 11039/pLSdam, and 11039/pLSdam2.

Mouse virulence assay. The virulence of 11039/pLSdam2 was compared to 11039 using a mouse model with five mice per treatment. Female 6-8 week old BALB/cJ mice were obtained from the Jackson Laboratory (Bar Harbor, ME USA), randomly divided into nine cages, and allowed to acclimate for one week. Bacterial broth cultures (11039 and 11039/pLSdam2) were incubated for 18 h and serially diluted in normal saline solution. Mice were injected intraperitoneally with 0.1 ml of an appropriate dose of either 11039 or 11039/pLSdam2. Four treatments were challenged with varying doses of 11039, four were challenged with 11039/pLSdam2, and one treatment was sham exposed to PBS. Mice were monitored for seven days, and mice surviving at the end of the challenge were euthanized.

Results

Phenotypic detection of Dam function in *P. multocida* and *M. haemolytica*. *Sau3A* I, *Dpn* I, and *Mbo* I all recognize and cleave GATC sequences. However, *Dpn* I only cleaves GATC sites whose adenine residue has been methylated, while *Mbo* I only cleaves unmethylated GATC sites. *Sau3A* I cleaves GATC sites regardless of methylation state. Therefore, differential digestion of bacterial genomic DNA with *Sau3A* I, *Dpn* I, and *Mbo* I can be used to detect Dam activity. Our results indicated that both *P. multocida* strain 11039 and *M. haemolytica* strain D153 have functional Dam activity (See Figure 1).

***P. multocida* A1 dam gene sequence results.** The *P. multocida* A1 *dam* sequence was found to be 99.4% identical to the published *P. multocida* A3 *dam* sequence (5 nucleotide differences). The deduced amino acid sequences of the *P. multocida* A1 and A3 Dam proteins were 100% identical.

As expected, the *P. multocida* *dam* gene had higher sequence identity with the *H. influenzae* *dam* gene than with the other reported bacterial *dam* gene sequences (Table 2). Among gram-negative species, the *dam* gene is well conserved across four families, with identities ranging between 50-60%. The *P. multocida* *dam* gene was the largest of the known *dam* gene sequences (Table 2). By CLUSTAL W alignment, the additional coding sequence for the *P. multocida* *dam* gene was located at the 5' end of

the gene, with an extra 39 bp at the 5' end of the gene compared to *H. influenzae dam* and an extra 72 bp at the 5' end compared to *dam* sequences from other species.

Table 2. DNA adenine methylase gene comparisons between *P. multocida* and other gram-negative species

5	Species	Size	Nucleotide	Amino acid	Accession
		(nucleotides)	identity	identity	
	<i>Pasteurella multocida</i>	903	-	-	AF411317
	<i>Haemophilus influenzae</i>	861	68.9	68.2	U32705
10	<i>Escherichia coli</i>	837	58.2	55.4	V00272
	<i>Salmonella enterica</i>	837	58.5	55.0	AE008860
	<i>Serratia marcescens</i>	813	57.4	51.9	X78412
	<i>Yersinia pseudotuberculosis</i>	816	52.1	51.3	AF274318
15	<i>Vibrio cholerae</i>	834	60.0	56.7	AF274317
	<i>Neisseria meningitidis</i>	816	57.2	47.2	AF091142

The *E. coli dam* gene is part of a superoperon that includes several genes under complex regulatory control³⁵. Immediately upstream of *E. coli dam* is *urf*, which is preceded by *aroB* and *aroK*. A 90 bp gap is between *aroB* and *urf*, and a 100 bp gap is between *aroK* and *urf*. The *aroK* and *aroB* products function in aromatic amino acid biosynthesis, while *urf* and *dam* are involved in cell cycle regulation. No promoter activity is located immediately of *E. coli dam*, but a weak promoter is located upstream of *urf* within the *aroB* sequence³⁵. Another strong promoter is located upstream of *aroB*.

By contrast, *aroB* in *P. multocida* is located immediately upstream of *dam* with only a 4 bp gap between the genes, which is similar to the arrangement in *H. influenzae*. Our promoter analysis detected a potential promoter upstream of *P. multocida dam*

within the *aroB* coding sequence. The 5' end of this promoter was located 115 bp upstream of the *P. multocida dam* start codon and had the sequence TGGAAA-17 bp-TAGCGT-5 bp-G.

Complementation of an *E. coli dam* mutant. As described above in Methods, pCLPm2 contains the *P. multocida dam* gene cloned in the opposite orientation of the *lacZ* promoter in pT7Blue, while pCLPm3 contains the *P. multocida dam* gene oriented downstream of the *lacZ* promoter in pBluescript. When they were transferred into *E. coli dam* mutant strain DG105, both plasmids were able to restore Dam function (See Figure 2). The pCLPm2 insert contained only 117 bp of native *P. multocida* chromosomal sequence upstream of the *dam* start codon; this indicated that the potential promoter identified within the 115 bp upstream of the *P. multocida dam* gene is functional.

Effect of *P. multocida dam* expression on spontaneous mutation frequency in *E. coli*. As expected, the spontaneous mutation frequency of *E. coli dam* mutant DG105 was significantly higher than the mutation rate of the parent wild type strain DG98 (Table 3). The mutation rate of DG105/pCLPm2 was also significantly higher than wild type, and although the mutation rate of DG105/pCLPm3 was not significantly higher than wild type, it was similar to the mutation rate for DG105/pCLPm2. DG105 had a higher mutation rate than both DG105/pCLPm2 and DG105/pCLPm3, although the difference was not statistically significant.

Table 3. Spontaneous mutation frequency in *E. coli* strains DG98, DG105, DG105/pCLPm2, and DG105/pCLPm3

Strain	Mutation rate*	Ratio†
DG98	0.24 ± 0.06 ^a	
DG105	7.43 ± 3.18 ^b	30.7
DG105/pCLPm2	4.85 ± 3.08 ^b	20.1
DG105/pCLPm3	4.33 ± 2.28 ^{ab}	17.9

*Number of mutants per 10⁷ CFU

†Ratio of mutation rate for the indicated strain divided by the mutation rate for DG98.

The increased mutation rates of DG105/pCLPm2 and DG105/pCLPm3 compared to wild type indicates that overexpression of the *P. multocida dam* gene causes increased spontaneous frequency in *E. coli*. Increased mutation frequency has already been demonstrated in *E. coli* overexpressing an *E. coli dam* gene³⁶. The mutation rates of DG105/pCLPm2 and DG105/pCLPm3 were similar; apparently the native *dam* promoter in pCLPm2 was just as effective in expressing *dam* in *E. coli* as the *lacZ* promoter.

Effect of *dam* overexpression in *P. multocida*. Plasmid pLSdam is similar to pCLPm2 in that the insert contains the *P. multocida dam* gene under the control of its native promoter, while pLSdam2 is similar to pCLPm3 in that *dam* is expressed from a *lac* promoter. Both plasmids were transferred into *P. multocida* 11039 to determine whether the native *dam* promoter would be as effective in causing overexpression in *P. multocida* as it was in *E. coli*.

Surprisingly, transfer of pLSdam actually lowered the spontaneous mutation rate of strain 11039 compared to the wild type strain, although the difference was not statistically significant (Table 4). However, 11039/pLSdam2 had a significantly higher spontaneous mutation rate compared to 11039, demonstrating that this strain had increased Dam activity and that the *lac* promoter was effective in causing *dam* overexpression in *P. multocida*.

Table 4. Spontaneous mutation frequency in *P. multocida* strain 11039, 11039/pLSdam, and 11039/pLSdam2

Strain	Mutation rate*	Ratio†
11039	0.30 ^a	
11039/pLSdam	0.14 ^a	0.47
11039/pLSdam2	2.37 ^b	7.9

*Number of mutants per 10⁷ CFU

†Ratio of mutation rate for the indicated strain divided by the mutation rate for 11039.

Mouse virulence assay. A mouse virulence trial indicated that 11039/pLSdam retained full virulence compared to 11039, which was expected because the mutation rates of 11039 and 11039/pLSdam were not significantly different. However, a virulence assay with 11039/pLSdam2 demonstrated that this strain was clearly attenuated in mice compared to wild type strain 11039. Mice exposed to wild type strain 11039 were injected with 11 CFU/mouse, 23 CFU/mouse, 113 CFU/mouse, and 227 CFU/mouse; all four doses had 100% mortality. Mice exposed to 11039/pLSdam2 were injected with 17 CFU/mouse, 86 CFU/mouse, 171 CFU/mouse, and 856 CFU/mouse; all four doses had 0% mortality. Sham control mice also had 0% mortality.

Discussion

The inventors have demonstrated the function of DNA adenine methylase from *P. multocida*, which is an important etiologic agent of BRD in cattle. In other bacterial species, Dam is important in regulating and coordinating several cell functions, including initiation of chromosome replication, DNA repair, and gene transcription. As a result of its role in DNA repair, bacteria with altered Dam activity have increased mutability. Its role in regulation of gene transcription, particularly genes involved in pathogenicity, causes strains with altered Dam activity to be attenuated. The inventors compared *P. multocida* Dam function to Dam proteins from other bacterial species by measuring the effects of altered Dam activity on these two phenotypes: spontaneous mutation frequency and virulence in a mouse model.

E. coli dam mutants have an increased rate of spontaneous mutations, increased sensitivity to ultraviolet radiation and to base analogues such as 2-aminopurine (2-AP), and inviability when combined with a *recA*, *recB*, or *recC* mutation³⁷⁻³⁹. Dam methylates DNA at the N⁶ position of adenine within GATC recognition sequences⁴⁰, which allows the methyl-directed mismatch repair system to distinguish between the template and nascent strands to correct misincorporated bases during DNA replication^{37,41}. Interestingly, overproduction of Dam also increases mutability because methylation of the daughter strand occurs too quickly, which also prevents the mismatch repair system from distinguishing between the template and daughter strands^{36,42}.

P. multocida Dam has 55% identity with *E. coli* Dam, and the inventors demonstrated that it is able to complement an *E. coli dam* mutant. In addition, overproduction of *P. multocida* Dam in *E. coli* caused an approximate 20-fold increase in the spontaneous mutation frequency. This result is similar to the effect of increased native Dam activity in *E. coli*; a mutant with 50-fold increase in Dam activity had a corresponding 30-fold increase in development of spontaneous rifampin resistance ³⁶.

The potential native *dam* promoter sequence identified on pCLPm2 (located within the *aroB* coding sequence) appeared relatively weak, having 5/12 mismatches compared to the *E. coli* consensus promoter. In *E. coli*, the promoter upstream of *dam* and *urf* located within the *aroB* coding sequence is also relatively weak, having 3- to 4-times less activity than another promoter located upstream of *aroB* ³⁵. Therefore, it was surprising that the spontaneous mutation frequency in DG105/pCLPm2 was similar to that of DG105/pCLPm3 because it was expected the *lac* promoter in pCLPm3 would cause increased Dam activity compared to the pCLPm2 construct with a concurrent increase in mutation frequency.

By comparison, when the *P. multocida dam* gene was expressed from its native promoter in strain 11039 using shuttle vector pLS88 (pLSdam), there was no significant increase in spontaneous mutation frequency. On the other hand, expression of *P. multocida dam* from a *lacZ* promoter in 11039 (pLSdam2) did cause increased spontaneous mutation frequency. One possible explanation for the different effects of the native *dam* promoter on spontaneous mutation frequency in *E. coli* and *P. multocida* is that the high copy number of pT7Blue, a pUC derivative, may be the cause of increased Dam production in *E. coli*. pLS88 is not likely to have as high copy numbers in *P. multocida*. Alternatively, *dam* expression from the native promoter may be subject to transcriptional regulation in *P. multocida*, and the transcriptional regulator that controls *dam* expression may not be present in *E. coli*, resulting in unrestricted expression.

Dam overproducing strains of *Salmonella enterica*, *Yersinia pseudotuberculosis*, and *Vibrio cholerae* are all attenuated ^{25,35}. Similarly, our Dam overproducing *P.*

multocida strain was attenuated using a mouse model. The attenuation of strains with altered *dam* expression is apparently due to “inappropriate” expression of virulence factors that results from the failure of Dam to regulate their transcription²⁵. In *Salmonella*, a similar attenuating effect occurs in *dam* deletion mutants²⁵; mutation of the *dam* gene is lethal in *Y. pseudotuberculosis* and *V. cholerae*²⁶.

Interestingly, the inappropriate expression of virulence factors in Dam altered strains not only causes attenuation, but it also renders them highly effective as live attenuated vaccines^{25,26,43}. Although *P. multocida* immunogens have been identified that have potential as vaccines^{44,45}, there is still a need for an effective *P. multocida* BRD vaccine. Killed bacterins have had little effect in preventing BRD⁴⁶; however, live vaccines have demonstrated efficacy⁴⁶⁻⁴⁸.

In the non-limiting example described above, the inventors have demonstrated that alteration of *dam* expression in *P. multocida* can enable the development of a live attenuated vaccine. It is entirely within the concept of the present invention to provide novel attenuated live bacteria vaccines for a wide range of other pathogens, which can include, for example, bacteria selected from the group including *Salmonella*, *E. Coli*, *Haemophilus*, *Streptococcus*, *Helicobacter*, *Shigella*, *Bibrio*, *Treponema*, *Yersinia*, *Neisseria*, *Porphyromonas*, *Legionella*, *Actinobacillus*, *Pasteurella*, *Mannheimia*, and the like.

In addition to the detailed discussion of a first embodiment of the present invention, alternative embodiments of the present invention include methods of altering Dam expression to obtain effective live vaccines by 1) altering the chromosomal promoter for the *dam* gene so as to alter Dam expression or 2) mutation of the *dam* gene so as to alter the expression of Dam in any of the above listed pathogenic bacteria. The bacteria having the altered chromosomal promoter for the *dam* gene or having a mutated *dam* gene then fails to properly express Dam and is rendered non-pathogenic and by altering Dam expression the bacteria is attenuated and is suitable for use in live attenuated bacterial vaccines.

In the first alternative embodiment, the promoter for the native *dam* gene in the

chromosome of one of the pathogens of the *Pasteurellaceae* family is replaced with a promoter that would cause increased Dam expression in the bacteria so as to render it non-pathogenic. It is also within the scope of the invention, that in this first alternative embodiment, the replacement promoter would cause decreased Dam expression in the bacteria, which would also serve to render the bacterial non-pathogenic and suitable for use as an attenuated live bacteria vaccine. Acceptable methods for the replacement of the promoter would be known and understood by one of ordinary skill in the art.

In a second alternative embodiment, the native *dam* gene in one of the pathogens of the *Pasteurellaceae* family is mutated. The mutation can be achieved either by using the cloned native *dam* gene from the pathogen to mutate the chromosomal copy of the *dam* gene by homologous recombination, or by transposon mutagenesis, or by site-directed mutagenesis.

Dam activity may be increased or decreased, and Dam activity may be altered on any level, including transcription and/or translation. With respect to translation, for example, activity can be altered in any number of ways, including the amount of protein produced and/or that nature (i.e., structure) of the protein produced. For example, a mutation could result in increasing or reducing the amount of Dam produced by the cell (due to affecting transcriptional and/or post-transcriptional events); alternatively, a mutation could give rise to an altered Dam with altered activity. Generating mutations and mutants which alter Dam activity use techniques, are well known in the art. For example in the first alternative embodiment of the present invention, Dam production can be increased or lowered by using a promoter which is known to initiate transcription at a higher or lower level. Assays to determine level of transcription from a given transcriptional regulatory element such as a promoter are well known in the art.

In the second alternative embodiment of the present invention, a different *dam* gene could be used that is known to produce higher or lower levels of Dam than is found in the wild type bacteria without departing from the scope of the inventor's discovery. Mutations can be made within the *dam* gene itself (including transcriptional and/or translational regulatory elements) as well as a gene or genes which affect Dam production and/or activity.

By one embodiment of the present invention, pathogenic bacteria are made

attenuated, preferably avirulent, as a result of a non-reverting mutation that is created in at least one gene, which thereby alters the expression of Dam. The regulation of genes by Dam is sensitive to Dam concentrations; therefore, over-expression of Dam as well as under-expression of Dam results in the attenuation of the pathogen. In the second
5 embodiment of the present invention, the mutation is preferably made in the *dam* gene itself, however, it is within the concept of the present invention that the vaccines according to the present invention may be produced by mutating a related gene or genes either upstream or downstream of the *dam* gene, whose expressed product activates or represses the *dam* gene or, in the alternative, a mutation is constructed in at least one
10 virulence gene that is regulated by Dam.

While a single non-reverting mutation provides a high degree of security against possible reversion to virulence, it is within scope of the invention to provide additional security in a second separate and unrelated mutation.

Further, while the present invention has been described with reference to
15 specific embodiments and exemplary bacteria species, it will be understood by those skilled in the art that a variety of changes may be made and the substitution of equivalents may be made without departing from the true spirit and scope of the present invention. Many modifications may be made to adapt a particular situation or a particular selected pathogen to the inclusive concept of the present invention. All such
20 modifications or adaptations are intended to be within the scope of the claims appended hereto.

The complete disclosure of all references cited in this application are fully incorporated herein by reference.

REFERENCES

1. Carter G. Observations on the pathology and bacteriology of shipping fever in Canada. *Can J Comp Med* 1954;18:359-64.
2. Collier J. Pasteurellae in bovine respiratory disease. *J Am Vet Med Assoc* 5 1969;140:807-10.
3. Scheifer B, Ward GE, Moffatt RE. Correlation of microbiological and histological findings in bovine fibrinous pneumonia. *Vet Pathol* 1978;15:313-321.
4. Purdy CW, Raleigh RH, Collins JK, et al. Serotyping and enzyme characterization of *Pasteurella haemolytica* and *Pasteurella multocida* isolates recovered 10 from pneumonic lungs of stressed feeder calves. *Curr Microbiol* 1997;34:244-9.
5. Allen JW, Viel L, Bateman KG, et al. The microbial flora of the respiratory tract in feedlot calves: associations between nasopharyngeal and bronchoalveolar lavage cultures. *Can J Vet Res* 1991;55:341-6.
6. Singer RS, Case JT, Carpenter TE, et al. Assessment of spatial and temporal 15 clustering of ampicillin- and tetracycline-resistant strains of *Pasteurella multocida* and *P. haemolytica* isolated from cattle in California. *J Am Vet Med Assoc* 1998;212:1001-5.
7. Gourlay RN, Thomas LH, Wyld SG. Experimental *Pasteurella multocida* pneumonia in calves. *Res Vet Sci* 1989;47:185-9.
8. Bryson DG, McFerran JB, Ball HJ, et al. Observations on outbreaks of 20 respiratory disease in housed calves--(1) Epidemiological, clinical and microbiological findings. *Vet Rec* 1978;103:485-9.
9. Virtala AM, Mechor GD, Grohn YT, et al. Epidemiologic and pathologic characteristics of respiratory tract disease in dairy heifers during the first three months of life. *J Am Vet Med Assoc* 1996;208:2035-42.
10. Boyce JD, Adler B. The capsule is a virulence determinant in the 25 pathogenesis of *Pasteurella multocida* M1404 (B:2). *Infect Immun* 2000;68:3463-8.
11. Rimler RB, Rebers PA, Phillips M. Lipopolysaccharides of the Heddleston serotypes of *Pasteurella multocida*. *Am J Vet Res* 1984;45:759-63.
12. Brogden KA, Rimler RB, Cutlip RC, et al. Incubation of *Pasteurella* 30 *haemolytica* and *Pasteurella multocida* lipopolysaccharide with sheep lung surfactant. *Am J Vet Res* 1986;47:727-9.

13. Confer AW, Suckow MA, Miloscio L, et al. Intranasal vaccination of rabbits with *Pasteurella multocida* a:3 OMPs and IROMPs. *Proc. Conf Res Workers Anim Dis 80th Ann Mtg.* 1999.
14. Geschwend G, Feist H, Erler W. [Investigation of outer membrane proteins of *Pasteurella*. 2: Iron-regulated outer membrane proteins of *Pasteurella multocida* and *Pasteurella haemolytica*]. *Berl Munch Tierarztl Wochenschr* 1997;110:386-90.
15. Negrete-Abascal E, Tenorio VR, de la Garza M. Secretion of proteases from *Pasteurella multocida* isolates. *Curr Microbiol* 1999;38:64-7.
16. Straus DC, Purdy CW, Loan RW, et al. In vivo production of neuraminidase by *Pasteurella haemolytica* in market stressed cattle after natural infection. *Curr Microbiol* 1998;37:240-4.
17. White DJ, Jolley WL, Purdy CW, et al. Extracellular neuraminidase production by a *Pasteurella multocida* A:3 strain associated with bovine pneumonia. *Infect Immun* 1995;63:1703-9.
18. Galdiero M, Palomba E, De L, et al. Effects of the major *Pasteurella multocida* porin on bovine neutrophils. *Am J Vet Res* 1998;59:1270-4.
19. Fuller TE, Kennedy MJ, Lowery DE. Identification of *Pasteurella multocida* virulence genes in a septicemic mouse model using signature-tagged mutagenesis. *Microb Pathog* 2000;29:25-38.
20. May BJ, Zhang Q, Li LL, et al. Complete genomic sequence of *Pasteurella multocida*, Pm70. *Proc Natl Acad Sci U S A* 2001;98:3460-5.
21. Blyn LB, Braaten BA, Low DA. Regulation of pap pilin phase variation by a mechanism involving differential *dam* methylation states. *Embo J* 1990;9:4045-54.
22. Braaten BA, Nou X, Kaltenbach LS, et al. Methylation patterns in pap regulatory DNA control pyelonephritis-associated pili phase variation in *E. coli*. *Cell* 1994;76:577-88.
23. van der Woude MW, Low DA. Leucine-responsive regulatory protein and deoxyadenosine methylase control the phase variation and expression of the *sfa* and *daa* pili operons in *Escherichia coli*. *Mol Microbiol* 1994;11:605-18.
24. Henderson IR, Owen P. The major phase-variable outer membrane protein of *Escherichia coli* structurally resembles the immunoglobulin A1 protease class of

exported protein and is regulated by a novel mechanism involving Dam and oxyR. *J Bacteriol* 1999;181:2132-41.

25. Heithoff DM, Sinsheimer RL, Low DA, et al. An essential role for DNA adenine methylation in bacterial virulence. *Science* 1999;284:967-70.

5 26. Julio SM, Heithoff DM, Provenzano D, et al. DNA adenine methylase is essential for viability and plays a role in the pathogenesis of *Yersinia pseudotuberculosis* and *Vibrio cholerae*. *Infect Immun* 2001;69:7610-5.

27. Fleischmann RD, Adams MD, White O, et al. Whole-genome random sequencing and assembly of *Haemophilus influenzae* Rd. *Science* 1995;269:496-512.

10 28. Palmer BR, Marinus MG. The *dam* and *dcm* strains of *Escherichia coli*--a review. *Gene* 1994;143:1-12.

29. Ausubel FM BR, Kingston RE, Moore DD, Seidman JG, Smith JA, Struhl K. Current Protocols in Molecular Biology. New York, New York: John Wiley and Sons, 1994.

15 30. Altschul SF, Madden TL, Schaffer AA, et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. *Nucleic Acids Res* 1997;25:3389-402.

31. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting,
20 position-specific gap penalties and weight matrix choice. *Nucleic Acids Res* 1994;22:4673-80.

32. Reese MG, Harris NL, Eeckman FH. Large scale sequencing specific neural networks for promoter and splice site recognition. Biocomputing: Proceedings of the 1996 Pacific Symposium 1996.

25 33. Willson PJ, Albritton WL, Slaney L, et al. Characterization of a multiple antibiotic resistance plasmid from *Haemophilus ducreyi*. *Antimicrob Agents Chemother* 1989;33:1627-30.

34. Jablonski L, Sriranganathan N, Boyle SM, et al. Conditions for transformation of *Pasteurella multocida* by electroporation. *Microb Pathog* 1992;12:63-
30 8.

35. Jonczyk P, Hines R, Smith DW. The *Escherichia coli dam* gene is expressed as a distal gene of a new operon. *Mol Gen Genet* 1989;217:85-96.
36. Herman GE, Modrich P. *Escherichia coli* K-12 clones that overproduce *dam* methylase are hypermutable. *J Bacteriol* 1981;145:644-6.
- 5 37. Glickman B, van den Elsen P, Radman M. Induced mutagenesis in *dam*-mutants of *Escherichia coli*: a role for 6-methyladenine residues in mutation avoidance. *Mol Gen Genet* 1978;163:307-12.
38. Bale A, d'Alarcao M, Marinus MG. Characterization of DNA adenine methylation mutants of *Escherichia coli* K12. *Mutat Res* 1979;59:157-65.
- 10 39. Marinus MG, Morris NR. Biological function for 6-methyladenine residues in the DNA of *Escherichia coli* K12. *J Mol Biol* 1974;85:309-22.
40. Geier GE, Modrich P. Recognition sequence of the *dam* methylase of *Escherichia coli* K12 and mode of cleavage of Dpn I endonuclease. *J Biol Chem* 1979;254:1408-13.
- 15 41. Modrich P. Methyl-directed DNA mismatch correction. *J Biol Chem* 1989;264:6597-600.
42. Marinus MG, Poteete A, Arraj JA. Correlation of DNA adenine methylase activity with spontaneous mutability in *Escherichia coli* K-12. *Gene* 1984;28:123-5.
43. Heithoff DM, Enioutina EY, Daynes RA, et al. *Salmonella* DNA adenine methylase mutants confer cross-protective immunity. *Infect Immun* 2001;69:6725-30.
- 20 44. Confer AW, Nutt SH, Dabo SM, et al. Antibody responses of cattle to outer membrane proteins of *Pasteurella multocida* A:3. *Am J Vet Res* 1996;57:1453-7.
45. Adler B, Bulach D, Chung J, et al. Candidate vaccine antigens and genes in *Pasteurella multocida*. *J Biotechnol* 1999;73:83-90.
- 25 46. Cardella MA, Adviento MA, Nervig RM. Vaccination studies against experimental bovine *Pasteurella pneumonia*. *Can J Vet Res* 1987;51:204-11.
47. Panciera RJ, Corstvet RE, Confer AW, et al. Bovine pneumonic pasteurellosis: effect of vaccination with live *Pasteurella* species. *Am J Vet Res* 1984;45:2538-42.

48. Chengappa MM, McLaughlin BG, Kadel WL, et al. Efficacy of a live *Pasteurella multocida* vaccine for the prevention of experimentally induced bovine pneumonic pasteurellosis. *Vet Microbiol* 1989;21:147-54.

WHAT IS CLAIMED IS:

1. An attenuated strain of a bacteria, said bacteria comprising altered DNA adenine methylase (Dam) activity such that the bacteria are attenuated.
2. The attenuated strain of Claim 1, wherein the altered activity reduces Dam activity.
3. The attenuated strain of Claim 2, wherein the altered activity eliminates Dam activity.
4. The attenuated strain of Claim 1, wherein the altered activity is obtained by a deletion in a *dam* gene.
5. The attenuated strain of Claim 1, wherein the altered activity is obtained by an increase in expression of Dam.
6. The attenuated strain of Claim 1, wherein the bacteria is an attenuated form of *Haemophilus*.
7. The attenuated strain of Claim 1, wherein the bacteria are an attenuated form of a bacteria selected from the group consisting of: *Salmonella enterica* serovars, *E. coli*, Non Typable *Haemophilus influenza*, *Streptococcus pneumoniae*, *Helicobacter pylori*, *Shigella* Spp., *Vibrio cholerae*, *Yersinia* Spp., *Neisseria meningitidis*, *Porphyromonas gingivalis*, and *Legionella pneumonophila*.
8. The attenuated strain of Claim 1, wherein the bacteria are an attenuated form of a bacteria selected from the group consisting of *Streptococcus pneumoniae*, *Neisseria meningitidis*, *Haemophilus somnus*, *Actinobacillus pleuropneumoniae*, *Pasteurella multocida*, and *Mannheimia haemolytica*.
9. The attenuated strain of Claim 1, wherein the altered activity is obtained by an artificially engineered change in a genome of a wild-type pathogenic bacteria.
10. The attenuated strain of Claim 9, wherein the change in the bacteria's genome is a change selected from the group consisting of a deletion, an insertion and a mutation of the native sequence.
11. The attenuated strain of Claim 1, wherein the altered activity is obtained by a heterologous nucleotide inserted into a wild-type pathogenic bacteria.
12. The attenuated strain of Claim 11, wherein the heterologous nucleotide is

operatively inserted into a plasmid and expresses DNA adenine methylase.

13. The attenuated strain of Claim 1, wherein the bacteria are an attenuated form of a pathogenic bacteria selected from the group consisting of *Escherichia*, *Vibrio*, *Yersinia* and *Salmonella*.

5 14. The attenuated strain of Claim 13, wherein the bacteria are an attenuated form of a pathogenic salmonella bacteria selected from the group consisting of *S. typhimurium*, *S. enteritidis*, *S. typhi*, *S. abortus-ovi*, *S. abortus-equi*, *S. dublin*, *S. gallinarum*, and *S. pullorum*.

10 15. The attenuated strain of Claim 13, wherein the bacteria are an attenuated form of *E. coli*.

16. The attenuated strain of Claim 13, wherein the bacteria are an attenuated form of *V. cholerae*.

17. The attenuated stain of Claim 13, wherein the bacteria are an attenuated form of *Y. pseudotuberculosis*.

15 18. The attenuated strain of Claim 1, wherein the bacteria are an attenuated form of a bacteria selected from the group consisting of *Shigella*, *Haemophilus*, *Bordetella*, *Neisseria*, *Pasteurella* and *Tremonema*.

19. The attenuated strain of Claim 1, wherein the bacteria are an attenuated form of a bacteria selected from the group consisting of *Streptococcus pneumoniae*,
20 *Neisseria meningitidis*, *Haemophilus somnus*, *Actinobacillus pleuropneumoniae*, *Pasterurella multocida*, and *Mannheimia haemolytica*.

20. The attenuated strain of Claim 1, wherein the bacteria are an attenuated form of *Haemophilus*.

21. A composition comprising: a pharmaceutically acceptable excipient; and
25 bacteria with altered DNA adenine methylase (Dam) activity which altered DNA adenine methylase activity renders the bacteria non-pathogenic.

22. The composition of Claim 21, further comprising an adjuvant.

23. An immunogenic composition comprising: a pharmaceutically acceptable excipient; and live bacteria comprising altered DNA adenine methylase activity wherein
30 the altered activity reduces virulence relative to the bacteria with wild-type Dam activity.

24. The immunogenic composition of Claim 23, wherein the Dam activity is altered by a heterologous nucleotide.

25. The immunogenic composition of Claim 23, wherein the Dam activity is altered by a mutation in the bacteria's genome which mutation alters a gene involved in expressing Dam in a manner selected from the group consisting of reduced expression, no expression, overexpression expression of a form of Dam altered from Dam native to the bacteria.

26. A method comprising steps of: administering to a subject capable of generating an immune response a composition comprising a pharmaceutically acceptable excipient, an immunogenic dose of altered bacteria with altered DNA adenine methylase (Dam) activity which bacteria are attenuated; and allowing the composition to remain in the subject for a time and under conditions to allow the subject to generate an immune response to the bacteria and produce antibodies specific to the bacteria.

27. The method of Claim 26, wherein the antibodies generated are IgG type antibodies.

28. The method of Claim 27, wherein the IgG antibodies are highly specific for an antigen of the bacteria.

29. The method of Claim 26, wherein the bacteria remain in the subject under conditions and for a period of time sufficient to allow for B cells of the subject to undergo isotype switching and further for the B cells to undergo clonal expansion.

30. The method of Claim 29, wherein an amount of antibodies produced by the subject exceeds 150% of an amount of antibodies which would be produced by the subject administered unaltered bacteria in amount equivalent to the immunogenic dose of altered bacteria.

31. The method of Claim 26, wherein the bacteria are selected from the group consisting of *Escherichia*, *Vibrio*, *Yersinia* and *Salmonella*.

32. The method of Claim 26, wherein the bacteria are *Haemophilus*.

33. A method of eliciting an immune response in an individual, comprising: administering an immunogenic composition to an individual in an amount sufficient to elicit an immune response wherein the composition comprises a pharmaceutically

acceptable carrier and a bacteria comprising a genome characterized by a mutation altering DNA adenine methylase (Dam) activity such that the bacteria is attenuated; allowing the composition to remain in the individual for a time and under conditions to allow the individual to generate an immune response.

5 34. The method of Claim 33, wherein the bacteria are *Haemophilus*.

35. An attenuated strain of a bacteria, said bacteria comprising a cloned *dam* gene capable of altered DNA adenine methylase (Dam) activity such that said bacteria are attenuated and suitable for use as a live vaccine.

10 36. The attenuated strain of Claim 35, wherein said altered activity increases Dam expression.

37. The attenuated strain of Claim 36, wherein said increased Dam expression is obtained by control of said cloned *dam* gene by a promoter.

15 38. The attenuated strain of Claim 37, wherein said promoter is selected from the group consisting of a *lac* promoter, *tac* promoter, *araBAD* promoter, *trc* promoter, *trp* promoter, T7, SP6, or T5 bacteriophage promoters, a native promoter from that species, or other appropriate promoter.

39. The attenuated strain of Claim 35, wherein said bacteria is a species of the *Pasteurellaceae* family.

20 40. The attenuated strain of Claim 35, wherein the bacteria are an attenuated form of a bacteria selected from the group consisting of *Pasteurella multocida*, *Mannheimia haemolytica*, *Actinobacillus pleuropneumoniae*, *Haemophilus somnus*, *Actinobacillus suis*, and *Haemophilus parasuis*.

25 41. A composition comprising:
a pharmaceutically acceptable carrier in combination with a bacteria demonstrating altered DNA adenine methylase (Dam) activity, said altered activity being overexpression of Dam,

whereby said overexpression of Dam renders the bacteria non-pathogenic and suitable as an attenuated live bacterial vaccine.

42. The composition of Claim 41, wherein said over expression is obtained by

control of said cloned *dam* gene by a promoter.

43. The composition of Claim 42, wherein said promoter is selected from the group consisting of a *lac* promoter, *tac* promoter, *araBAD* promoter, *trc* promoter, *trp* promoter, T7, SP6, or T5 bacteriophage promoters, a native promoter from that species, or other appropriate promoter.

44. The composition of Claim 41, wherein said bacteria is a species of the *Pasteurellaceae* family.

45. The composition of Claim 41, wherein said bacteria are an attenuated form of a bacteria selected from the group consisting of *Pasteurella multocida*, *Mannheimia haemolytica*, *Actinobacillus pleuropneumoniae*, *Haemophilus somnus*, *Actinobacillus suis*, and *Haemophilus parasuis*.

46. A method of producing an attenuated live vaccine comprising:
cloning a *dam* gene of a bacterial species into a plasmid;

said plasma comprising a promoter capable of controlling the expression of said *dam* gene;

introducing said plasmid to a wild type of said bacteria species so as to produce bacteria which demonstrate altered DNA adenine methylase (Dam) activity such that said bacteria are rendered non-pathogenic and suitable for use as an attenuated live bacterial vaccine.

47. The method of Claim 46, wherein said expression of said *dam* gene is overexpressed.

48. The method of Claim 47, wherein said overexpression is obtained by control of said cloned *dam* gene by a promoter.

49. The method of Claim 48, wherein said promoter is selected from the group consisting of a *lac* promoter, *tac* promoter, *araBAD* promoter, *trc* promoter, *trp* promoter, T7, SP6, or T5 bacteriophage promoters, a native promoter from that species, or other appropriate promoter.

50. The method of Claim 46, wherein said bacteria is a species of the *Pasteurellaceae* family.

51. The method of Claim 46, wherein the bacteria are an attenuated form of a bacteria selected from the group consisting of *Pasteurella multocida*, *Mannheimia*

haemolytica, *Actinobacillus pleuropneumoniae*, *Haemophilus somnus*, *Actinobacillus suis*, and *Haemophilus parasuis*.

52. The method of Claim 46, wherein said plasmid is stabilized by treating a mutation in a chromosome of said bacteria, said mutation being lethal to said bacteria under predetermined conditions.

53. A method of providing a level of immunity to infection by a pathogenic bacteria comprising:

providing an attenuated strain of bacteria, said attenuated strain comprising a cloned *dam* gene capable of altered DNA adenine methylase (Dam) activity such that said bacteria are attenuated and suitable for use as a live vaccine;

providing a pharmaceutically acceptable carrier;

combining said attenuated strain of bacterial with said carrier to produce a dose of vaccine suitable for use by a subject capable of being infected by said bacteria;

administering to said subject said dose of vaccine in sufficient quantity to illicit an immune response to said pathogenic bacteria, said response being sufficient to produce antibodies to said pathogenic bacteria.

54. The method of Claim 53, wherein said altered Dam activity increases Dam expression.

55. The method of Claim 54, wherein said increased Dam expression is obtained by control of said cloned *dam* gene by a promoter.

56. The method of Claim 55, wherein said promoter is selected from the group consisting of a *lac* promoter, *tac* promoter, *araBAD* promoter, *trc* promoter, *trp* promoter, T7, SP6, or T5 bacteriophage promoters, a native promoter from that species, or other appropriate promoter.

57. The method of Claim 53, wherein said bacteria is a species of the *Pasteurellaceae* family.

58. The method of Claim 53, wherein the bacteria are an attenuated form of a bacteria selected from the group consisting of *Pasteurella multocida*, *Mannheimia haemolytica*, *Actinobacillus pleuropneumoniae*, *Haemophilus somnus*, *Actinobacillus suis*, and *Haemophilus parasuis*.

59. A method of producing an attenuated live vaccine comprising:

providing a pathogenic bacteria having a *dam* gene and a chromosomal promoter for said *dam* gene;

altering the chromosomal promoter for said *dam* gene,

whereby said altered promoter of said *dam* gene causes altered
5 expression of DNA adenine methylase (Dam) by said pathogenic bacteria such that said pathogenic bacteria are rendered non-pathogenic and suitable for use as an attenuated live bacterial vaccine.

60. The method of Claim 59, wherein said expression of said *dam* gene is overexpressed.

10 61. The method of Claim 59, wherein said altering of said promoter comprises replacement of said promoter.

62. The method of Claim 61, wherein said promoter is selected from the group consisting of a *lac* promoter, *tac* promoter, *araBAD* promoter, *trc* promoter, *trp* promoter, T7, SP6, or T5 bacteriophage promoters, a native promoter from that species,
15 or other appropriate promoter.

63. The method of Claim 59, wherein said bacteria is a species of the *Pasteurellaceae* family.

64. The method of Claim 59, wherein the bacteria are an attenuated form of a bacteria selected from the group consisting of *Pasteurella multocida*, *Mannheimia*
20 *haemolytica*, *Actinobacillus pleuropneumoniae*, *Haemophilus somnus*, *Actinobacillus suis*, and *Haemophilus parasuis*.

65. A method of providing a level of immunity to infection by a pathogenic bacteria comprising:

providing an attenuated strain of bacteria, said attenuated strain comprising a
25 bacteria having a *dam* gene under the control of an altered promoter and being capable of altered DNA adenine methylase (Dam) activity such that said bacteria are attenuated and suitable for use as a live vaccine;

providing a pharmaceutically acceptable carrier;

combining said attenuated strain of bacterial with said carrier to produce a dose
30 of vaccine suitable for use by a subject capable of being infected by said bacteria;

administering to said subject said dose of vaccine in sufficient quantity to illicit

an immune response to said pathogenic bacteria, said response being sufficient to produce antibodies to said pathogenic bacteria.

66. The method of Claim 65, wherein said altered Dam activity increases Dam expression.

5 67. The method of Claim 65 wherein said altered Dam activity decreases Dam expression.

68. The method of Claim 65, wherein said promoter is selected from the group consisting of a *lac* promoter, *tac* promoter, *araBAD* promoter, *trc* promoter, *trp* promoter, T7, SP6, or T5 bacteriophage promoters, a native promoter from that species, or other appropriate promoter.

10 69. The method of Claim 65, wherein said bacteria is a species of the *Pasteurellaceae* family.

70. The method of Claim 65, wherein the bacteria are an attenuated form of a bacteria selected from the group consisting of *Pasteurella multocida*, *Mannheimia haemolytica*, *Actinobacillus pleuropneumoniae*, *Haemophilus somnus*, *Actinobacillus suis*, and *Haemophilus parasuis*

71. A method of producing an attenuated live vaccine comprising:
 providing a pathogenic bacteria having a native *dam* gene;
 causing a genetic alteration affecting said *dam* gene,
20 whereby said alteration of said *dam* gene causes altered expression of DNA adenine methylase (Dam) by said pathogenic bacteria such that said pathogenic bacteria are rendered non-pathogenic and suitable for use as an attenuated live bacterial vaccine.

72. The method of Claim 71, wherein said genetic alteration comprises replacing said native *dam* gene of said pathogenic bacteria with a different *dam* gene.

73. The method of Claim 71, wherein said genetic alteration comprises causing a mutation of said native *dam* gene of said pathogenic bacteria.

74. The method of Claim 73, wherein said mutation of said native *dam* gene comprises using a cloned native *dam* gene of said pathogenic bacteria and mutating said native *dam* gene by a method selected from the group consisting of homologous

recombination, transposon mutagenesis and site directed mutagenesis.

75. The method of Claim 71, wherein said expression of said *dam* gene is overexpressed.

5 76. The method of Claim 71, wherein said expression of said *dam* gene is reduced.

77. The method of Claim 71, wherein said bacteria is a species of the *Pasterurellaceae* family.

78. The method of Claim 71, wherein the bacteria are an attenuated form of a bacteria selected from the group consisting of *Pasteurella multocida*, *Mannheimia*
10 *haemolytica*, *Actinobacillus pleuropneumoniae*, *Haemophilus somnus*, *Actinobacillus suis*, and *Haemophilus parasuis*.

79. The method of Claim 71, wherein said genetic alteration affecting said *dam* gene comprises causing a mutation in at least one gene other than said *dam* gene, said at least one gene being upstream or downstream of said *dam* gene and capable of affecting
15 Dam production or activity.

80. The method of Claim 71, wherein said altered Dam expression comprises altered Dam having less activity than Dam expressed by native pathogenic bacteria.

81. A method of providing a level of immunity to infection by a pathogenic bacteria comprising:

20 providing an attenuated strain of bacteria, said attenuated strain comprising a bacteria having a *dam* gene, said *dam* gene expressing altered DNA adenine methylase (Dam) activity such that said bacteria are attenuated and suitable for use as a live vaccine;

providing a pharmaceutically acceptable carrier;

25 combining said attenuated strain of bacterial with said carrier to produce a dose of vaccine suitable for use by a subject capable of being infected by said bacteria;

administering to said subject said dose of vaccine in sufficient quantity to illicit an immune response to said pathogenic bacteria, said response being sufficient to produce antibodies to said pathogenic bacteria.

30 82. The method of Claim 81, wherein said altered Dam activity increases Dam expression.

83. The method of Claim 81 wherein said altered Dam activity decreases Dam expression.

84. The method of Claim 81, wherein said bacteria is a species of the *Pasteurellaceae* family.

5 85. The method of Claim 81, wherein the bacteria are an attenuated form of a bacteria selected from the group consisting of *Pasteurella multocida*, *Mannheimia haemolytica*, *Actinobacillus pleuropneumoniae*, *Haemophilus somnus*, *Actinobacillus suis*, and *Haemophilus parasuis*.

ABSTRACT

Live attenuated bacteria vaccines are provided. Also provided are methods by which such vaccines can be obtained, including: a method by which a copy of the *dam* gene from a pathogenic bacteria is cloned into a plasmid capable of replication in the same bacteria species such that it is overexpressed from either a *lac* promoter, *tac* promoter, *araBAD* promoter, *trc* promoter, *trp* promoter, T7, SP6, or T5 bacteriophage promoters, a native promoter from that species, or other appropriate promoter. The plasmid containing the *dam* gene is then transferred into the pathogens to cause increased expression of Dam resulting in the formation of a live attenuated bacterial vaccines. Alternative methods for producing the vaccine are also provided including altering or replacing the chromosomal promoter for the native *dam* gene so as to alter Dam expression or mutating or replacing the native *dam* gene so as to alter the expression of Dam in a pathogenic bacteria.


FIGURE 1

FIGURE 2

